Future of Biofinancing — When Science Meets the Stock Exchange, Insurance and Capital Markets
Nineteen funding nodes, from a campus prize competition to the trading floor.
Prologue — Two Worlds That Never Meet
A local skincare company has capital, a factory and distribution — but no formula strong enough for the premium segment. On the other side of the city, thousands of students and young researchers are sitting on brilliant formulas that have stalled for lack of funding. Missing link is just one thing: a financial mechanism that bridges the two at every stage.
This is what biofinancing sets out to answer — applying modern financial instruments (futures exchanges, insurance, grants, debt, digital assets, and capital-market instruments such as receivables assignment, securitisation, green bonds and public share offerings) to science and biotechnology research, alongside sustainability instruments (ecosystem services, carbon credits, producer responsibility). Follow the journey of Sari and her formula — from an innovation competition to shares traded on the exchange — through nineteen funding nodes.
Act 0 — A Spark Born from a Competition
Scheme: Innovation Challenge
A consortium of three national skincare companies, together with BRIN, opens a competition for a local anti-ageing active ingredient. Sari, a final-year pharmacy undergraduate, enters with an extract of pegagan (Centella asiatica); out of 340 proposalss, hers reaches the top five. Industry "fishes" for the best ideas through open competition, with prize money that doubles as seed capital for research.
| Total prize fund (consortium + BRIN) | Rp500.000.000 |
|---|---|
| Proposals received | 340 proposals |
| 1st place (Sari’s proposal) | Rp150.000.000 |
| 2nd place | Rp100.000.000 |
| 3rd–5th place (each) | Rp50.000.000 |
| 1st-place bonus: incubator + 6 months of mentorship | Included in the package |
Act 1 — A Thesis That Does Not End on a Library Shelf
Scheme: Licensing Undergraduate, Master’s and Doctoral Theses
Sari completes her thesis with an asiaticoside concentration far above commercial products. Thousands of theses and dissertations are a neglected "gold mine". Through sciencepreneur.com her finding is registered with curator validation; a skincare company takes a non-exclusive licence (upfront fee plus royalties), and the university takes a share as institutional IP holder.
| Non-exclusive licence upfront fee | Rp150.000.000 |
|---|---|
| Royalty | 5% of net sales |
| Estimated first-year serum sales | Rp2.000.000.000 |
| First-year royalty | Rp100.000.000 |
| Sari’s total first-year income | Rp250.000.000 |
| University share (20%) | Rp50.000.000 |
Act 2 — Closing the Gap Before Standing Alone
Scheme: Grant Matching
Developing a high-concentration version requires pre-clinical testing (toxicity, dermal irritation, stability). Too early for equity investors, too advanced for a basic grant. Grant matching pairs a government or philanthropic grant with matching industry funding (1:1) — the burden is shared, and selection is tighter.
| Funding needed for full pre-clinical testing | Rp400.000.000 |
|---|---|
| Government/philanthropic grant (1:1 matching) | Rp200.000.000 |
| Industry partner co-funding | Rp200.000.000 |
| Total funds raised | Rp400.000.000 |
| Contribution from Sari’s own pocket | Rp0 |
Act 3 — Raising Capital to Build a House of Her Own
Scheme: Equity Crowdfunding & Private Matchmaking
The tests pass; Sari founds a spin-off, Pegagan Labs. Equity Crowdfunding opens shares to the public (retail investors receive proportional ownership); Private Matchmaking brings in strategic investors to scale from lab to pilot plant.
| Pre-money valuation | Rp4.500.000.000 |
|---|---|
| Funds offered to the public | Rp500.000.000 |
| Post-money valuation | Rp5.000.000.000 |
| Equity released | 10% |
| Number of retail investors | 500 people (±Rp1 m each) |
| Valuation at scale-up | Rp10.000.000.000 |
|---|---|
| Strategic investor funding | Rp1.500.000.000 |
| Equity released | 15% |
| Form | Cash plus mentorship |
Act 4 — Locking the Formula Before a Competitor Takes It
Scheme: IP Forward Contract
A large company wants to lock exclusive rights to the high-concentration version, still a year away from completing stability testing. A forward contract on the IP: the deposit is paid via escrow → the funds complete the testing; once it passes, the balance is settled and the exclusive licence transfers.
| Exclusive licence price | Rp800.000.000 |
|---|---|
| Upfront deposit (40%, escrow) | Rp320.000.000 |
| Funding for 1 year of stability testing | Rp320.000.000 |
| Balance (60%) on passing | Rp480.000.000 |
Act 5 — Growing Without Constantly Giving Away Ownership
Scheme: Venture Debt
The product sells; ARR passes Rp1 billion. To scale production without dilution, venture debt is a loan based on revenue projections rather than physical collateral, at a higher interest rate plus a warrant.
| ARR at application | Rp1.200.000.000 |
|---|---|
| Venture debt facility | Rp800.000.000 |
| Annual interest | 14% (Rp112 m/year) |
| Warrant coverage | 2% |
| Dilution avoided (vs ~8% for equity) | ~6% |
Act 6 — Receivables Locked on the Distributor’s Shelf
Scheme: Cessie (Assignment of Receivables / Factoring)
Pegagan Labs supplies more than 60 outlets, but distributors pay only after 60–90 days. Profitable on paper, tight in the bank account. Cessie (factoring / invoice financing): the right to collect is transferred to a financing institution, and cash is released upfront less a fee. Because it is without recourse, the default risk transfers as well.
| Total receivables from 60 distributors (90-day terms) | Rp1.200.000.000 |
|---|---|
| Type of cessie | Without recourse |
| Financing fee/discount (4%) | Rp48.000.000 |
| Cash released upfront (96%) | Rp1.152.000.000 |
| Time to disbursement | 3 working days (vs 90 days) |
| Default risk | Transferred to the financing institution |
Act 7 — Protecting Margins from Currency Swings
Scheme: Biomaterial Futures
Clinical-grade imported inputs (emulsifiers, premium preservatives) are exposed to exchange rates. Hedging with a futures contract: lock today's price for delivery in six months.
| Raw material required | 500 kg |
|---|---|
| Current price (per kg) | Rp1.500.000 |
| Total if locked today | Rp750.000.000 |
| 6-month projection (rupiah −15%) | Rp1.725.000 / kg |
| Total at market price in six months | Rp862.500.000 |
| Real saving | Rp112.500.000 |
Act 8 — Protecting the Source Before Protecting the Margin
Scheme: Payment for Ecosystem Services (PES)
The best extract quality comes from wild pegagan at the edge of a buffer forest managed by dozens of farming families. When that area is threatened with conversion, the supply chain is threatened too. PES pays those who keep an environmental service in existence, rather than buying the commodity itself — annual compensation on condition that the area is not converted and harvesting stays sustainable.
| Buffer area protected | 120 hectares |
|---|---|
| Farming households benefiting | 40 families |
| PES payment per hectare per year | Rp2.500.000 |
| Total PES per year | Rp300.000.000 |
| Pegagan Labs contribution (40%) | Rp120.000.000 |
| Philanthropic conservation fund contribution (60%) | Rp180.000.000 |
Act 9 — The Residue That Turns Out Not to Be Waste
Scheme: Waste-to-Resource Monetisation
The pegagan extraction residue, once a cost burden, is now processed by an agritech startup into organic compost and biomass pellets (boiler fuel replacing part of the gas supply). The equipment is installed under a small-scale built-operate-transfer arrangement, with profits shared.
| Biomass waste volume per month | 8,000 kg |
|---|---|
| Equipment investment (BOT by partner) | Rp180.000.000 |
| Compost revenue per month (Rp3,500/kg) | Rp11.200.000 |
| Industrial gas cost saved per month | Rp9.000.000 |
| Profit-sharing split | 50 : 50 |
| Total combined benefit per month | Rp20.200.000 |
Act 10 — Turning Future Royalties into Cash Today
Scheme: Blockchain Digital Assets (Royalty Tokenisation)
The future royalty stream is tokenised into a digital asset and sold to global investors; distribution runs automatically through a smart contract, and it can be traded on the secondary market.
| Projected future royalties (5 years) | Rp1.000.000.000 |
|---|---|
| Present value (12%/year discount) | Rp650.000.000 |
| Number of tokens | 650,000 tokens at Rp1,000 |
| Cash received today | Rp650.000.000 |
| Royalty distribution | Automatic each quarter (smart contract) |
Act 11 — Selling Clean Air to the Capital Market
Scheme: Carbon Exchange (Carbon Credit Trading)
The PES programme (Act 8) plus energy efficiency (Act 9) amount to a measurable tonnage of emissions avoided or absorbed. Once verified by an independent certification body, carbon credits are issued and traded on the Indonesia Carbon Exchange — bought by corporations that need an offset or a net-zero target.
| Emissions reduced (PES + efficiency) per year | 1,800 tonnes CO2e |
|---|---|
| Carbon credit price (assumed) | Rp80,000 / tonne CO2e |
| Potential revenue per year | Rp144.000.000 |
| Certification & verification cost per year | Rp35.000.000 |
| Net carbon credit revenue per year | Rp109.000.000 |
Act 12 — Building a Factory That Does Not Burden the Planet
Scheme: Green Bonds
The second factory is designed green from the foundations up (solar panels, wastewater recycling, green building). Green bond are bonds whose proceeds may only fund projects meeting environmental criteria, verified through a green bond framework + second party opinionand a second party opinion, and reported on periodically.
| Green bond issued | Rp3.000.000.000 |
|---|---|
| Tenor · coupon | 5 years · 8.5% |
| Proceeds — solar panels & renewables | Rp1.200.000.000 |
| Proceeds — wastewater recycling | Rp900.000.000 |
| Proceeds — green building construction | Rp900.000.000 |
| Reporting obligation | Annual environmental impact report |
Act 13 — Moving Up to the Institutional Capital Market
Scheme: Securitisation (Asset-Backed Securities)
Working-capital needs jump to institutional scale. Sekuritisasi pools many assets (assigned receivables, multi-licence royalties, export projections) into a Special Purpose Vehicle, then issues Asset-Backed Securities (ABS) sold to institutional investors after being assessed by a rating agency.
| Total assets pooled (receivables + 5 years of royalties) | Rp5.000.000.000 |
|---|---|
| SPV | PT Pegagan Aset Sekuritas |
| Rating | idA (investment grade) |
| ABS issued (90%) | Rp4.500.000.000 |
| Annual coupon · tenor | 9% · 3 years |
| Main investors | Pension funds & insurers |
Act 14 — Responsibility That Does Not Stop at the Till
Scheme: Extended Producer Responsibility (EPR) Financing
Regulation requires producers to draw up a roadmap for reducing post-consumer packaging waste. EPR financing pool: several cosmetics producers jointly fund one shared recycling infrastructure, contributing in proportion to their own packaging volume.
| Pegagan Labs packaging volume per year | 45 tonnes |
|---|---|
| Management target (EPR roadmap) | 30% of volume |
| Shared infrastructure fund (association) | Rp2.000.000.000 |
| Pegagan Labs contribution (~6%) | Rp120.000.000 |
| Penalty for non-compliance | Administrative fine & reputational risk |
Act 15 — Selling the Care, Not Just the Bottle
Scheme: Product-as-a-Service (PaaS)
A subscription service called "Ritual" is born: subscribers receive a refill pouch each month, and return the reusable glass bottle to be refilled. PaaS turns a one-off transaction into recurring revenue (MRR) — which can then be pledged through revenue-based financing.
| "Ritual" subscribers | 8,000 subscribers |
|---|---|
| Subscription fee per month | Rp150.000 |
| Monthly recurring revenue (MRR) | Rp1.200.000.000 |
| Packaging return rate | 78% |
| Revenue-based financing (3× MRR) | Rp3.600.000.000 |
| Cost of funding | 6% of MRR |
Act 16 — From the Campus Noticeboard to the Trading Floor
Scheme: Initial Public Offering (IPO)
Ten years after the competition, Pegagan Labs is ready to list on the Indonesia Stock Exchange. The IPO provides substantial expansion funding, a liquid exit for early investors (the Act 3 crowdfunding, the venture debt warrant), and the standing of a public company.
| Valuation ahead of IPO | Rp85.000.000.000 |
|---|---|
| Shares offered (free float) | 20% |
| Offer price per share | Rp1.700 |
| Funds raised in the IPO | Rp17.000.000.000 |
| Oversubscription | 3.2× |
| Status after IPO | Public company (OJK & IDX) |
Act 17 — Managing Cash Flow Without Selling Assets
Scheme: Repurchase Agreement (Repo)
As a listed company, Pegagan Labs holds part of its cash in securities. When a temporary liquidity gap opens up, the finance team runs a repo: selling securities with a promise to buy them back at an agreed price and date — an ultra-short secured loan, not an asset sale.
| Value of securities repo’d | Rp1.000.000.000 |
|---|---|
| Tenor | 30 days |
| Repo interest | 6.5%/year (~Rp5.4 m over 30 days) |
| Cash released upfront | Rp994.600.000 |
| Ownership after settlement | Returns fully to Pegagan Labs |
Act 18 — When an Experiment Can Fail in a Second
Scheme: R&D Failure Protection
Pure technical risk shadows every stage — a power cut or contamination can kill an entire culture. Research failure insurance: a single premium upfront, full cover, with claims verified by an independent auditor.
| Value of research batch insured | Rp300.000.000 |
|---|---|
| Premium (3%, one-off upfront) | Rp9.000.000 |
| External short-circuit scenario | Occurs |
| Claim paid out | Rp300.000.000 |
Epilogue — One Formula, Nineteen Funding Nodes
All nineteen schemes complement one another across the life cycle of a single piece of research:
| The spark of an idea | Innovation Challenge |
|---|---|
| Academic idea | Thesis Licensing |
| Advanced research, pre-startup | Grant Matching |
| Founding the entity, high risk | Crowdfunding & Private Matchmaking |
| Nearing completion, needs finishing capital | IP Forward Contract |
| Revenue traction begins | Venture Debt |
| Regular sales, receivables piling up | Cessie (Assignment of Receivables) |
| Production / scale-up | Biomaterial Futures |
| Safeguarding supply sustainability | Payment for Ecosystem Services |
| Efficiency & waste management | Waste-to-Resource Monetization |
| Royalties already flowing | Digital Asset / Blockchain |
| Measurable environmental impact | Carbon Exchange |
| Expanding environmentally friendly facilities | Green Bonds |
| Large scale, needs institutional investors | Securitisation (ABS) |
| Post-consumer compliance | EPR Financing |
| Circular business model | Product-as-a-Service |
| Peak growth, needs standing & an exit | IPO |
| Cash management for a listed company | Repo |
| Throughout the entire R&D process | R&D Failure Protection |
Scientific research and industry in Indonesia have long run on separate tracks — researchers speak the language of the laboratory, investors the language of the balance sheet. Biofinancing arrives as the translator between them: turning risk into instruments that can be calculated, traded and managed together — from the first competition to the initial public offering. The future of Indonesian science is not only about who researches most cleverly, but who assembles the funding instruments most shrewdly.
This article is part of the sciencepreneur.com education series on innovative financial instruments for Indonesia's research and biotechnology ecosystem. Written by Ahmad Maulana Faqih.